Journal Article

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

Clark, Jeffrey W, Ou, Sai-Hong I, Shaw, Alice T, Stephenson, Patricia, Kwak, Eunice L, Fox, Stephen B, Fidias, Panagiotis, LoRusso, Patricia, Iafrate, A John, Salgia, Ravi, Tang, Yiyun, Ruffner, Katherine, Jänne, Pasi A, Varella-Garcia, Marileila, Engelman, Jeffrey A, Gandhi, Leena, Shapiro, Geoffrey I, Costa, Daniel B, Camidge, D Ross, Kim, Dong-Wan, Riely, Gregory J, Solomon, Benjamin, Bang, Yung-Jue, Wilner, Keith

2012

Overview

ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs). We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identified to have an ALK fusion within the first-in-man phase 1 crizotinib study. In this phase 1 study, patients with ALK-positive stage III or IV NSCLC received oral crizotinib 250 mg twice daily in 28-day cycles. Endpoints included tumour responses, duration of response, time to tumour response, progression-free survival (PFS), overall survival at 6 and 12 months, and determination of the safety and tolerability and characterisation of the plasma pharmacokinetic profile of crizotinib after oral administration. Responses were analysed in evaluable patients and PFS and safety were analysed in all patients. This study is registered with ClinicalTrials.gov, number NCT00585195. Between Aug 27, 2008, and June 1, 2011, 149 ALK-positive patients were enrolled, 143 of whom were included in the response-evaluable population. 87 of 143 patients had an objective response (60·8%, 95% CI 52·3–68·9), including three complete responses and 84 partial responses. Median time to first documented objective response was 7·9 weeks (range 2·1–39·6) and median duration of response was 49·1 weeks (95% CI 39·3–75·4). The response rate seemed to be largely independent of age, sex, performance status, or line of treatment. Median PFS was 9·7 months (95% CI 7·7–12·8). Median overall survival data are not yet mature, but estimated overall survival at 6 and 12 months was 87·9% (95% CI 81·3–92·3) and 74·8% (66·4–81·5), respectively. 39 patients continued to receive crizotinib for more than 2 weeks after progression because of perceived ongoing clinical benefit from the drug (12 for at least 6 months from the time of their initial investigator-defined disease progression). Overall, 144 (97%) of 149 patients experienced treatment-related adverse events, which were mostly grade 1 or 2. The most common adverse events were visual effects, nausea, diarrhoea, constipation, vomiting, and peripheral oedema. The most common treatment-related grade 3 or 4 adverse events were neutropenia (n=9), raised alanine aminotransferase (n=6), hypophosphataemia (n=6), and lymphopenia (n=6). Crizotinib is well tolerated with rapid, durable responses in patients with ALK-positive NSCLC. There seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed. Pfizer.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Adult / Aged / Aged, 80 and over / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - enzymology / Carcinoma, Non-Small-Cell Lung - mortality / Female / Hematology, Oncology and Palliative Medicine / Humans / Lung Neoplasms - drug therapy / Lung Neoplasms - enzymology / Lung Neoplasms - mortality / Male / Metastasis / Middle Aged / Oncology / Patients / Pleural effusion / Protein Kinase Inhibitors - adverse effects / Protein Kinase Inhibitors - therapeutic use / Pyrazoles - adverse effects / Pyrazoles - therapeutic use / Pyridines - adverse effects / Pyridines - therapeutic use / Receptor Protein-Tyrosine Kinases - analysis / Receptor Protein-Tyrosine Kinases - antagonists & inhibitors